Age-specific serum prostate-specific antigen references range among healthy men in Port Harcourt, Nigeria: a retrospective hospital-based study

Collins Amadi, Ehimen P. Odum


Background: Total prostate-specific antigen (PSA) levels increase with advancing age. Its age-specific ranges are being advocated to increase its sensitivity and specificity. This study was aimed to examine the relationship between total PSA levels and age, and to determine the age-specific ranges among healthy men without prostatic diseases in our environment.

Methods: In this retrospective hospital-based study, records of men without prostatic diseases who had visited University of Port Harcourt Teaching Hospital for routine screening for prostate cancer using serum total PSA between 1st January 2012 and 31st December 2016 were retrieved and analyzed using descriptive statistics and Spearman’s correlation test. A p-value < 0.05 was considered significant.

Results: Records of 476 men aged 38 to 86 years were recruited for the study. The age-specific total PSA reference range using the 95th percentile total PSA concentration values in each 10year groups were 0-1.60, 0-4.93, 0-6.93, 0-7.80, 0-9.65, and 0-13.30 for the age groups 30-39, 40-49, 50-59, 60-69, 70-79 and >80years respectively. There was a positive correlation between serum PSA concentration and age (rs = 0.395; p<0.001).

Conclusions: Total PSA increases with advancing age and its age-specific reference range in this study are similar to findings in our environment but higher than the values found in other parts of the world. We suggest serum PSA normal reference values should be characterized by age and race in our environment.


Age, Age-specific, Nigeria, Prostate cancer, Reference

Full Text:



Haas GP, Sakr WA. Epidemiology of Prostate Cancer. CA Cancer J Clin. 1997;47(5):237-87.

Siegel RL, Miller KD, Jemal AJ. Cancer Statistics. CA Cancer J Clin. 2017;67(1):7-30.

Ogunbiyi JO, Shittu OB. Increased Incidence of Prostate cancer in Nigerians. J Natl Med Asso. 1999;91(3):159-64.

Obiorah CC, Nwosu SO. A Histopathological Study of Prostate cancer in Port Hacourt, Nigeria. Niger J Clin Pract. 2011;14(3):363-67.

Heyns CF, Mathe S, Isaac A, Kharwa A, DE Beer PM, Pretorius MA. Problems with Prostate-specific Antigen in the Primary Healthcare Setting in South Africa. BJU Int. 2003;91(9):785-8.

Angelis GD, Rittenhouse HG, Mikolajczyk SD, Shamel LB, Semjonow A. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol. 2007;9(3):113-23.

Henderson RJ, Eastham IA, Culkin DJ, Whatley T, Mata J, Venable D, et al. Prostate-specific Antigen (PSA) and PSA Density: Racial Differences in Men without Prostate Cancer. J Natl Cancer Inst. 1997;89(2):134-8.

Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of Prostate cancer. Cancer. 1993;71(6):2031-40.

Collins GN, Lee RJ, Mckelvie GB, Rogers AC, Hemir M. Relationship between prostate-specific antigen, prostate volume and age in benign prostate. Br J Urol. 1993;71(4):445-50.

Osterling JE. Using Prostate-specific Antigen to eliminate unnecessary diagnostic test: Significant worldwide economic implications. Urology. 1995;46(suppl 3A):26-33.

Ikuerowo SO, Ajala MO, Abolarinwa AA, Omisanjo OA. Age-specific serum prostate-specific antigen ranges among apparently healthy Nigerian men without clinical evidence of prostate cancer. Niger J Surg. 2016;22(1):5-8.

Morgan T, Jacobson SJ, Mccarthy WF, Jacobson DB, McLeod DG, Moul JW, et al. Age-specific reference ranges for Prostate-specific Antigen in Black men. N Engl J Med. 1996(95);335:304-10.

Lein M, Koenig F, Jung F, McGovern FJ, Skates, SJ, Schnor, D, et al. The prevalence of free PSA is an age-independent tumor marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol. 1998;82(2):231-6.

Liu ZY, Sun YH, Xu CL, Gao XU, Zhang LM, Ren SC, et al. Age specific-specific reference ranges in Chinese men without Prostate cancer. Asian J Androl. 2009;11(1):100-3.

Muezzinoglu T, Lekili M, Eser E, Uyanik BS, Buyuksu C. Population Standards of Prostate-specific Antigen Values in Men over 40: community-based study in Turkey. Int Urol Nephrol. 2005;37(2):299-304.

Oesterling JE, Jacobson SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum Prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific references ranges. JAMA. 1993;270(7):860-4.

Etawo US, Ekeke ON, Aleme BM. Prospective study of sex hormone levels among prostate cancer patients attending the University of Port Harcourt Teaching Hospital. Niger Health J. 2012;12(2):29-42.

Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Mansumor N, et al. Serum prostate-specific antigen in a community-based population of healthy-Japanese men: lower values for similarly age-white men. Br J Urol. 1995;75(3):347-53.

Ima K, Ichinose Y, Kubota, Yamanaka H, Sato J. Diagnostic significance of Prostate Specific antigen and the development of a mass screening system for prostate cancer. J Urol. 1995;154:1085-9.

Shibata A, Whitemore AS, Imai K, Kolonel LN, Wu AH, John EN, et al. Serum levels of prostate specific antigen among Japanese-American and native Japanese men. J Natl cancer inst. 1997;89(22):1716-20.